Three whey protein polypeptides with xanthine oxidase inhibitory activity and preparation methods and applications thereof

By developing whey protein polypeptides with xanthine oxidase inhibitory activity, the problem of major side effects of existing uric acid-lowering drugs has been solved, and the effective uric acid-lowering and renal function protection effect on hyperuricemia has been achieved.

CN118307658BActive Publication Date: 2024-12-06CHINA AGRI UNIV +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410527310.2
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-04-29
Publication Date
2024-12-06
Estimated Expiration
2044-04-29

AI Technical Summary

Technical Problem

The existing uric acid-lowering drugs have great side effects and single functions, and lack effective and safe drugs for the prevention and treatment of hyperuricemia patients, especially in asymptomatic patients.

Method used

Three whey protein polypeptides with xanthine oxidase inhibitory activity and their preparation methods were developed. The peptides with xanthine oxidase inhibitory activity were obtained by enzymatic treatment of whey protein, and their uric acid-lowering effect was verified through animal experiments.

Benefits of technology

It significantly reduces serum uric acid levels, improves hyperuricemia and related renal impairment, and provides safe and effective prevention and treatment options.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118307658B_ABST
    Figure CN118307658B_ABST
Patent Text Reader

Abstract

The present invention proposes three kinds of whey protein xanthine oxidase inhibitory peptides, namely KIDAL, KFDKAL, KGYGGV, and their half inhibition concentrations are 4.34 ± 0.91, 6.74 ± 0.64, 7.75 ± 0.25mM, respectively, and work in synergy. Further, the present invention has confirmed that whey protein peptides KIDAL, KFDKAL, KGYGGV have a certain improvement effect on hyperuricemia rats at the in vivo level, mainly showing a reduction in serum uric acid, creatinine, uric acid nitrogen content in hyperuricemia rats, inhibiting the activity of xanthine oxidase (XOD) and adenosine deaminase (ADA) in rat serum and liver, inhibiting the synthesis of uric acid, and improving rat kidney damage. Therefore, the whey protein peptides obtained by the present invention can alleviate hyperuricemia diseases, and provide a scientific basis for functional foods, special medical foods, drug development and industrial production.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the field of biotechnology, and specifically relates to three whey protein polypeptides with xanthine oxidase inhibitory activity and preparation methods and applications thereof. Background Art

[0002] Hyperuricemia is a chronic disease, and changes in dietary structure have led to a surge in the number of patients with hyperuricemia. According to large-scale epidemiological studies, hyperuricemia has become a serious public health problem. The prevalence of HUA in China reached 14.00% in 2018-2019, and the prevalence in men was higher than that in women. Hyperuricemia is mainly caused by impaired purine metabolism or reduced uric acid excretion. The disease has a higher incidence in middle-aged and elderly people and is associated with diseases such as gout, cardiovascular and cerebrovascular diseases, diabetes, and cancer. In the human body, increased blood uric acid levels are associated with abnormal nucleic acid metabolism and reduced renal excretion. Uric acid is produced in the liver. During the production process, there are key enzymes that regulate purine metabolism. The production of uric acid in the body can be reduced by targeted inhibition of xanthine oxidase (XOD), etc. Xanthine oxidase is a non-specific hydroxylase that can catalyze hypoxanthine into xanthine, and xanthine is further catalyzed into uric acid. The substrates of XOD are generally purine, pyrimidine, pterin, aromatic heterocycles and certain aldehydes. The substrates bind to the active center site of XOD, and xanthine oxidase inhibitors can also bind to the active center of XOD, hindering the hydroxylation reaction of the substrate, thereby inhibiting the activity of XOD. The production of uric acid is hindered, and the level of uric acid in serum is ultimately reduced accordingly. Maintaining the level of uric acid in human serum is extremely important for human health, so xanthine oxidase can be used as a key target for the treatment of hyperuricemia.

[0003] Currently, the uric acid-lowering drugs on the market have significant side effects, such as allergic reactions and renal damage, and are mainly suitable for gout patients. However, there is a lack of effective and safe drugs for the prevention and treatment of patients with asymptomatic hyperuricemia. The "Third National Health and Nutrition Survey of the United States" found that people who drink milk once or more a day have lower blood uric acid levels than those who do not drink milk, and low-fat and skim milk have the most significant uric acid-lowering effect. Most of the uric acid-lowering products on the market do not add milk raw materials, and their functions are relatively simple. In addition to having a certain uric acid-lowering function, milk powder can participate in many important physiological activities of the human body because it is rich in protein, fat, lactose, amino acids and other nutrients, and has great benefits for maintaining human health. Many studies have shown that the peptides produced by whey protein hydrolysis have good bioavailability and safety, and show significant uric acid degradation effects in vivo. However, relevant reports on the specific preparation method of whey protein hydrolysis and specific whey protein peptide sequences need to be supplemented and improved. Therefore, the research and development of xanthine oxidase inhibitory active peptides obtained based on whey protein hydrolysis has important scientific research and clinical application prospects. Summary of the invention

[0004] The purpose of the present invention is to overcome the deficiencies of the prior art and to provide three whey protein polypeptides having xanthine oxidase inhibitory activity and preparation methods and applications thereof.

[0005] In order to achieve the above objectives, in a first aspect, the present invention provides a whey protein polypeptide having xanthine oxidase inhibitory activity, wherein the amino acid sequence of the peptide is as shown in any one of SEQ ID NO: 1 or SEQ ID NO: 2 or SEQ ID NO: 18, or an amino acid sequence having at least 85% identity thereto.

[0006] The above peptides are derived from whey protein.

[0007] In a second aspect, the present invention provides a nucleic acid molecule encoding the above-mentioned peptide, or a nucleotide sequence having at least 85% identity thereto.

[0008] The above nucleic acid molecule is DNA or RNA.

[0009] In a third aspect, the present invention provides an expression vector, the nucleotide sequence of which comprises the above-mentioned nucleic acid molecule.

[0010] In a fourth aspect, the present invention provides a recombinant cell, which is obtained by introducing the above-mentioned expression vector into a host cell.

[0011] In a fifth aspect, the present invention provides a pharmaceutical composition comprising the peptide described in the first aspect, or the nucleic acid molecule described in the second aspect, or the expression vector described in the third aspect, or the recombinant cell described in the fourth aspect.

[0012] In a sixth aspect, the present invention provides a method for preparing a whey protein xanthine oxidase inhibitory activity enzymatic hydrolysate, the method comprising the following steps:

[0013] S1. The whey protein solution is enzymatically treated with alkaline protease to obtain a whey protein hydrolysate;

[0014] S2. The whey protein hydrolysate obtained in S1 is purified and identified to obtain a xanthine oxidase inhibitory peptide.

[0015] The enzymatic treatment time of the above method is 1 to 5 hours.

[0016] In the seventh aspect, the present invention provides the use of the peptide described in the first aspect, or the nucleic acid molecule described in the second aspect, or the expression vector described in the third aspect, or the recombinant cell described in the fourth aspect, or the pharmaceutical composition described in the fifth aspect, or the method described in the sixth aspect in inhibiting xanthine oxidase activity.

[0017] In an eighth aspect, the present invention provides use of the peptide described in the first aspect, or the nucleic acid molecule described in the second aspect, or the expression vector described in the third aspect, or the recombinant cell described in the fourth aspect, or the pharmaceutical composition described in the fifth aspect, or the method described in the sixth aspect in the preparation of a drug for preventing and / or treating hyperuricemia. BRIEF DESCRIPTION OF THE DRAWINGS

[0018] Figure 1 The effect of different enzymatic hydrolysis time on the xanthine oxidase inhibitory activity of whey enzymatic hydrolysate.

[0019] Figure 2 It is the component of whey protein hydrolysate after gel filtration chromatography.

[0020] Figure 3 It is the xanthine oxidase inhibition rate of different components of whey protein hydrolysate obtained by gel filtration chromatography.

[0021] Figure 4 Figure 2 shows the xanthine oxidase inhibitory activity of nine potential whey protein uricosuric peptides.

[0022] Figure 5 This is a graph showing the xanthine oxidase inhibitory activity of different whey protein uricosuric peptide compositions.

[0023] Figure 6 This is the xanthine oxidase IC50 graph of KIDAL, KFDKAL, and KGYGGV polypeptides.

[0024] Figure 7 This is a graph showing the effects of serum uric acid on rats in different animal experimental groups.

[0025] Figure 8 The following are the effect diagrams of serum renal function indexes in rats in different animal experimental groups. A is the effect diagram of serum creatinine in rats; B is the effect diagram of serum urea nitrogen in rats.

[0026] Fig. 9 The activity graphs of xanthine oxidase and adenosine deaminase in rat serum and liver in different animal experimental groups. A is the activity graph of rat serum xanthine oxidase; B is the activity graph of rat liver xanthine oxidase; C is the activity graph of rat serum adenosine deaminase; D is the activity graph of rat liver adenosine deaminase.

[0027] Fig.10 The figure shows the effects on renal pathological tissue of rats in different animal experimental groups. DETAILED DESCRIPTION

[0028] The following will be combined with the drawings in the embodiments of the present invention to clearly and completely describe the technical solutions in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.

[0029] Example 1 Preparation of whey protein hydrolysate with uric acid lowering activity

[0030] In this example, a bovine whey concentrated protein hydrolysate having uric acid lowering inhibitory activity was prepared by the following method:

[0031] (1) whey protein was dissolved in distilled water at a ratio of 5%, and the whey protein was enzymatically hydrolyzed by alkaline protease at a ratio of 5% (w / w) of enzyme to substrate at 37°C;

[0032] (2) After 0 h, 0.25 h, 0.5 h, 1 h, 2 h, 3 h, 4 h, and 5 h of enzymatic hydrolysis, samples were taken and heated at 85 °C for 20 min to inactivate the enzyme;

[0033] (3) adjusting the pH value of the enzymatic hydrolysate to 7.0, and freeze-drying to obtain a whey enzymatic hydrolysate;

[0034] (4) Determine the xanthine oxidase (XOD) inhibition rate of the hydrolysates obtained at different hydrolysis times.

[0035] (5) Xanthine oxidase inhibitory activity assay method:

[0036] In this experiment, the inhibition rate of xanthine oxidase was determined to characterize the uric acid-lowering activity of the sample. The specific steps are as follows: 250 μL of the sample solution to be tested and 250 μL of xanthine oxidase were added to a 2 mL centrifuge tube, incubated at 37 °C for 10 min, and then 750 μL of xanthine solution was added to start the reaction. The reaction was continued at 37 °C for 15 min. After the reaction, 400 μL of 1 M hydrochloric acid was added to terminate the reaction. 5 μg / mL of allopurinol and 50 mM Tris-HCl buffer were used as positive and negative controls, respectively. The sample was passed through a 0.22 μm PES membrane. The HPLC conditions were: chromatographic column: C18 column (250×4.6 mm, 5 μm); mobile phase: 85% 10 mM NH4H2PO4 aqueous solution and 15% methanol; flow rate: 0.8 mL / min; UV: 290 nm. A 50 μM uric acid solution was used as a standard to determine the retention time of uric acid. Quantitative calculation was performed based on the corresponding peak area according to the retention time.

[0037]

[0038] like Figure 1As shown in the figure, the study found that whey protein hydrolysates under different hydrolysis time conditions all have XOD inhibitory activity. As the hydrolysis time increases, the hydrolysis degree and XOD inhibition rate gradually increase. When the hydrolysis time reaches 4h, the XOD inhibition rate reaches the highest, which can be further identified.

[0039] Example 2 Purification of whey protein hydrolysate with uric acid lowering activity

[0040] The present invention also provides a method for purifying a whey protein hydrolysate having uric acid-lowering activity:

[0041] (1) Use pure water to soak the dextran gel for activation. Boil it in water at 100°C for about 1 to 2 hours to allow the dextran gel to swell completely and remove the floating particles above the liquid.

[0042] (2) Place the chromatography column on an iron stand, slowly add the dextran gel into the column along the column wall, and balance the column with twice the column volume of pure water.

[0043] (3) Add the reserved whey protein hydrolysate solution into the chromatographic column, use pure water to carry the components forward, and adjust the flow rate.

[0044] (4) Collect the sample using a computer-controlled partial collector, control one tube every 5 minutes, collect the liquid in the test tube according to the absorbance, dry it to obtain whey protein peptides, and set aside. This experiment uses the inhibition rate of xanthine oxidase to characterize the uric acid-lowering activity of the sample. The specific steps are as follows: Take 250 μL of the sample solution to be tested and 250 μL of xanthine oxidase and add them to a 2 mL centrifuge tube. After incubation at 37°C for 10 minutes, add 750 μL of xanthine solution to start the reaction, continue incubation at 37°C for 15 minutes, and add 400 μL of 1M hydrochloric acid to terminate the reaction after the reaction. Use 5 μg / mL allopurinol and 50 mM Tris-HCl buffer as positive and negative controls, respectively. The sample is passed through a 0.22 μm PES membrane. HPLC conditions are: chromatographic column: C18 column (250×4.6mm, 5μm); mobile phase: 85% 10mM NH4H2PO4 aqueous solution and 15% methanol; flow rate: 0.8mL / min; UV: 290nm. A 50μM uric acid solution is used as a standard to determine the retention time of uric acid. Quantitative calculation is performed based on the retention time and the corresponding peak area.

[0045]

[0046] like Figure 2 As shown, after the whey protein hydrolysate was eluted through a Sephadex G-25 gel column, three peaks were obtained, namely, three components F1, F2, and F3 were obtained. After each component was collected, a 5 mg / mL solution was prepared for the activity determination of xanthine oxidase. Figure 3 As shown, the xanthine oxidase inhibition rates of the hydrolysate and the three components were 40.34±1.15%, 57.64±0.83%, 66.28±1.96% and 77.43±1.51%, respectively, that is, the uric acid-lowering activity of the F3 component was the best component.

[0047] Example 3 Identification of amino acid sequences of polypeptides with uric acid-lowering activity in whey protein hydrolysate

[0048] (1) Peptide sequence identification: Liquid chromatography-electrospray ionization tandem mass spectrometry (LC-ESI MS / MS) was used to identify the peptide sequence. The whey protein hydrolysate was dissolved in a 0.1% formic acid solution, and then the HPLC system was connected to a mass spectrometer equipped with an electrospray ionization source. The first-order spectral detection scanning range was 50-1500 m / z, the scanning resolution was 60000, and the secondary spectral scanning range was 50-1400 m / z, and the scanning resolution was 15000. The mobile phase A was 0.1% (v / v) formic acid, and the mobile phase B was 80% acetonitrile (containing 0.1% formic acid). During the elution process, solvent B was increased from 8% to 50% (v / v) at a flow rate of 200 nL / min.

[0049] (2) LC-ESI MS / MS data were collected and compared with UniProt (https: / / www.uniprot.org / ) and NCBI databases to identify the amino acid sequences of peptides in whey protein hydrolysates. According to ToxinPred and AllergenFP predictions, the peptides were non-toxic and most of them were non-allergenic. The amino acid sequences of the peptides identified from whey protein hydrolysates are shown in Table 1.

[0050] (3) Shanghai Nuoyou Biotechnology Co., Ltd. was commissioned to synthesize potential uric acid-lowering peptides through solid phase synthesis.

[0051] Table 1 Amino acid sequences of peptides obtained by identification of whey protein hydrolysate in Example 1

[0052]

[0053]

[0054] Example 4 Study on the xanthine oxidase activity of potential whey protein uricosuric peptides

[0055] In this experiment, the inhibition rate of xanthine oxidase was determined to characterize the uric acid-lowering activity of the sample. The specific steps are as follows: 250 μL of the sample solution to be tested and 250 μL of xanthine oxidase were added to a 2 mL centrifuge tube, incubated at 37 °C for 10 min, and then 750 μL of xanthine solution was added to start the reaction. The reaction was continued at 37 °C for 15 min. After the reaction, 400 μL of 1 M hydrochloric acid was added to terminate the reaction. 5 μg / mL of allopurinol and 50 mM Tris-HCl buffer were used as positive and negative controls, respectively. The sample was passed through a 0.22 μm PES membrane. The HPLC conditions were: chromatographic column: C18 column (250×4.6 mm, 5 μm); mobile phase: 85% 10 mM NH4H2PO4 aqueous solution and 15% methanol; flow rate: 0.8 mL / min; UV: 290 nm. A 50 μM uric acid solution was used as a standard to determine the retention time of uric acid. Quantitative calculation was performed based on the corresponding peak area according to the retention time.

[0056]

[0057] like Figure 4 As shown in the figure, according to the in vitro experimental results, the 9 synthetic peptides all have certain xanthine oxidase inhibitory activity at 100 μg / mL, but the analysis found that the inhibitory activity of KIDAL, KFDKAL, and KGYGGV was significantly greater than that of other peptides, all greater than 70%, and the effect was better than other peptides. The production of uric acid in the body is mainly controlled by purine metabolism-related enzymes, among which xanthine oxidase (XOD) is the key enzyme regulating uric acid production. The main function of xanthine oxidase is to catalyze the oxidation of hypoxanthine to xanthine, and then further oxidize to uric acid. Its substrates include purine, pyrimidine, pterin, aromatic heterocycles and certain aldehydes. Therefore, by inhibiting the activity of xanthine oxidase, the production of uric acid can be inhibited, and the active effect of lowering uric acid can be achieved. The higher the inhibitory activity of xanthine oxidase, the better the uric acid lowering activity of the peptide. Therefore, according to the experimental results, the whey protein uric acid lowering active peptides KIDAL, KFDKAL, and KGYGGV with better effects were selected for subsequent experiments to determine the synergistic effect and IC of the three peptides. 50 value.

[0058] In order to further explore the synergistic effect of the three whey protein xanthine oxidase inhibitory peptides, the three whey protein xanthine oxidase inhibitory peptides were arranged and combined to determine their synergistic inhibitory activity of xanthine oxidase. The specific combinations and results are shown in Tables 2 and Figure 5 As shown, the group of KIDAL and KFDKAL had the strongest synergistic effect among all the dual-peptide combinations, with an inhibitory activity of 91.54±1.87%.

[0059] Table 2 Combination of three whey protein uricosuric peptides

[0060]

[0061]

[0062] The xanthine oxidase inhibitory activity results of the three peptides alone are as follows Figure 6 As shown in the results, the half-inhibitory concentrations of whey protein xanthine oxidase inhibitory peptides KIDAL, KFDKAL, and KGYGGV are 4.34±0.91, 6.74±0.64, and 7.75±0.25 mM, and the three synthetic peptides all have good xanthine oxidase inhibitory concentrations. The half-inhibitory concentration represents the concentration of the substrate when the inhibition rate is 50%. The smaller the value, the better the inhibitory effect. Therefore, the inhibitory activity of short-chain polypeptides is relatively better. Whey protein inhibitory peptides can inhibit the synthesis of uric acid by inhibiting the activity of xanthine oxidase, thereby playing a role in lowering uric acid.

[0063] Example 5 Verification of uric acid-lowering activity of whey protein in vivo

[0064] Animal experiments were conducted using whey protein uric acid-lowering active peptides KIDAL, KFDKAL, and KGYGGV. Details are as follows:

[0065] 1. Experimental subjects

[0066] Thirty-six SD male rats (weight 200 g ± 20 g) were housed at 23 ± 3 °C, 65 ± 5% humidity, 12 h light-dark cycle, and good ventilation. Before the experiment, the rats were housed for 1 week to adapt to the experimental environment.

[0067] 2. Experimental Grouping

[0068] The rats were randomly divided into negative control group (NC group), hyperuricemia group (HUA group), allopurinol group, KIDAL group, KFDKAL group, and KGYGGV group (6 rats in each group).

[0069] 3. Experimental plan

[0070] Model establishment: rats in the NC group were gavaged with distilled water, and rats in the other groups were gavaged with potassium oxonate 1.5 g / kg BW once a day for 7 consecutive days. When the serum uric acid concentration of rats was greater than 110 μmol / L, the model was successfully established.

[0071] Starting from the eighth day, 1 hour after oral administration of potassium oxonate, the HUA group was given distilled water by gavage, the allopurinol group was given 20 mg / kg BW allopurinol by gavage, and the KIDAL group, KFDKAL group, KGYGGV group were given KIDAL, KFDKAL, KGYGGV peptide solutions by gavage, respectively.

[0072] The body weight, diet and health status of all rats were checked daily. When taking blood samples, 3% sodium pentobarbital (30 mg / kg BW) was injected intraperitoneally for anesthesia, and then blood samples were collected from the retroorbital plexus. The blood samples were centrifuged at 3000×g for 15 min at 4°C to obtain serum for further physiological analysis. Serum samples were collected three times on the 7th, 14th and 21st days of administration. The rats were killed on the 28th day, and blood, liver and kidney were collected and stored at -80°C for testing.

[0073] The uric acid level in the blood sample on the 7th day was measured. If the serum uric acid concentration was greater than 110 μmol / L, the model was successfully established. Then, allopurinol and whey protein xanthine oxidase inhibitory peptide were gavaged, and the uric acid level in the animal serum was measured on the 14th and 21st days. After the rats were killed, blood was collected, and commercial detection kits were used to measure uric acid, blood creatinine (Cr) and urea nitrogen (BUN) in the serum, as well as xanthine oxidase (XOD) and adenosine deaminase (ADA) in the serum and liver.

[0074] 4. Experimental results

[0075] like Figure 7 As shown in the figure, it can be seen that after one week of intragastric administration, the uric acid level of hyperuricemia rats was greater than 110 μmol / L, which means that the hyperuricemia model was successfully established. After three weeks of intervention, the serum uric acid level of normal rats in the NC group was 83.83±3.32 μmol / L, but the serum uric acid level of hyperuricemia rats in the HUA group reached 201±5.9 μmol / L. The uric acid content of rats in the KIDAL group, KFDKAL group, KGYGGV group and allopurinol group decreased significantly, among which the serum uric acid level in the allopurinol group decreased to 85.33±2.94 μmol / L, gradually returning to normal levels compared with the NC group. The serum uric acid levels of HUA rats in the KIDAL group, KFDKAL group and KGYGGV group were significantly decreased compared with the HUA group, indicating that the whey protein xanthine oxidase inhibitory active peptides KIDAL, KFDKAL and KGYGGV have the potential to develop into anti-hyperuricemia drug candidates.

[0076] In clinical reports, serum creatinine and urea nitrogen are important indicators for evaluating renal function. Serum Cr and BUN are closely related to serum uric acid levels. Serum Cr and BUN levels in patients with hyperuricemia will increase, indicating abnormal renal function and pathological damage to the kidneys. Figure 8As shown in the results, after oral administration of potassium oxonate, the serum Cr and BUN of rats in the HUA group increased significantly, which is consistent with the trend reported. Compared with the HUA group, the urea nitrogen and creatinine levels of the KIDAL group, KFDKAL group, and KGYGGV group were significantly lower than those of the HUA group. The results showed that supplementation with the polypeptide provided by the present invention can alleviate hyperuricemia and related renal function damage.

[0077] Active purine metabolic pathways or reduced uric acid excretion can easily lead to uric acid accumulation in the body and develop into hyperuricemia. XOD and ADA play an important role in the purine metabolism process, helping purine to convert into uric acid. When the activity of ADA and XOD in serum and liver is too high, it will lead to excessive uric acid production and thus hyperuricemia. The effect of the application example of the present invention on the activity of XOD in rat serum and liver is shown in the following figure. Fig. 9 As shown in A and B, the serum XOD activity of normal rats in the NC group was 31.98±0.96U / L, and the liver XOD activity was 16.15±0.84U / g prot. The XOD activity in the serum and liver of the hyperuricemia rats in the HUA group was significantly increased compared with the normal rats in the NC group. However, after oral administration of positive drugs in the allopurinol group, there was no significant difference in the XOD activity in the serum and liver between the NC group and the allopurinol group, and the XOD activity returned to normal levels. After oral administration of whey protein peptides, the serum and liver XOD activity of the KIDAL group, KFDKAL group, and KGYGGV group was significantly reduced compared with the HUA group. Although it was not as good as allopurinol, it had an improvement effect on the activity of XOD in the serum and liver of hyperuricemia rats. These results show that in hyperuricemia rats, the serum and liver XOD activity is enhanced, resulting in increased production of uric acid, thereby inducing the occurrence of hyperuricemia. The whey protein xanthine oxidase inhibitory active peptides in the KIDAL group, KFDKAL group, and KGYGGV group can reduce the activity of XOD in serum and liver, thereby reducing the production of uric acid by inhibiting the activity of key enzymes in uric acid synthesis, thereby alleviating the symptoms of hyperuricemia rats.

[0078] The application example of the present invention affects the activity of ADA in rat serum and liver. The results are as follows: Fig. 9 As shown in C and D, the serum ADA activity of the NC group was 7.95±0.96U / L, and the liver ADA activity was 18.33±1.17U / g prot. The serum ADA activity and liver ADA activity of the hyperuricemia rats in the HUA group were significantly increased compared with those of normal rats. The liver XOD activity and ADA activity of the hyperuricemia rats after gavage of allopurinol, KIDAL, KFDKAL and KGYGGV whey protein xanthine oxidase inhibitory active peptide solution were significantly decreased, inhibiting the activity of key enzymes for uric acid production in the liver.

[0079] Histopathological images of kidneys Fig.10It shows that obvious pathological changes occurred in the HUA group, with glomerular atrophy at the black arrow, obvious tubular dilatation at the yellow arrow, and cell brush border shedding. Under the action of the positive drug allopurinol, the rat kidneys improved. Compared with the NC group, the glomeruli were fuller and the cell dense gaps were small. Similarly, after gavage with KIDAL, KFDKAL and KGYGGV whey protein xanthine oxidase inhibitory active peptide solutions, the kidneys of hyperuricemia rats also improved significantly. These results show that gavage of hyperuricemia rats with the whey protein xanthine oxidase inhibitory active peptide mentioned in the present invention can improve their damage to renal function.

[0080] The above is only a preferred embodiment of the present invention. It should be pointed out that for ordinary technicians in this technical field, several improvements and modifications can be made without departing from the technical principles of the present invention. These improvements and modifications should also be regarded as the scope of protection of the present invention.

Claims

1. A whey protein polypeptide having xanthine oxidase inhibitory activity, characterized in that: The amino acid sequence of the peptide is shown in SEQ ID NO:

2.

2. The peptide according to claim 1, characterized in that The peptides are derived from whey protein.

3. A nucleic acid molecule, characterized in that The nucleic acid molecule encodes the peptide according to claim 1 or 2, and the nucleic acid molecule is DNA or RNA.

4. An expression vector, characterized in that: The nucleotide sequence of the expression vector comprises the nucleic acid molecule of claim 3.

5. A recombinant cell, characterized in that The recombinant cell is obtained by introducing the expression vector according to claim 4 into a host cell.

6. A pharmaceutical composition, characterized in that The pharmaceutical composition comprises the peptide according to claim 1 or 2, or the nucleic acid molecule according to claim 3, or the expression vector according to claim 4, or the recombinant cell according to claim 5.

7. Use of the peptide according to claim 1 or 2, or the nucleic acid molecule according to claim 3, or the expression vector according to claim 4, or the recombinant cell according to claim 5, or the pharmaceutical composition according to claim 6 in the preparation of a product for inhibiting xanthine oxidase activity.

8. Use of the peptide according to claim 1 or 2, or the nucleic acid molecule according to claim 3, or the expression vector according to claim 4, or the recombinant cell according to claim 5, or the pharmaceutical composition according to claim 6 in the preparation of a drug for preventing and / or treating hyperuricemia.